Prenatal Assessment and Screening
Prenatal assessment and screening is the set of clinical and laboratory methods used during pregnancy to evaluate maternal and fetal health, confirm and date the pregnancy, and estimate the probability that the fetus is affected by a chromosomal, genetic, or structural condition. It combines imaging, maternal biochemistry, cell-free DNA analysis, and genetic carrier testing to inform counselling and further diagnostic options.
Definition
Prenatal assessment and screening comprises the methods applied during pregnancy to characterize the pregnancy and to estimate or detect fetal abnormalities, distinguishing population-level screening tests, which quantify risk, from diagnostic tests, which confirm or exclude a specific condition.
Scope
This area orients the reader to the major streams of antenatal evaluation: confirming and dating the pregnancy, obstetric ultrasound, maternal serum and cell-free DNA screening, detection of aneuploidy and structural anomalies, and carrier screening for inherited conditions. It frames screening as risk estimation that precedes, and is distinct from, diagnostic testing. It is a reference overview and does not provide individualized clinical instructions.
Sub-topics
Core questions
- How is a pregnancy confirmed and accurately dated?
- What does obstetric ultrasound contribute at each stage of pregnancy?
- How do maternal serum markers and cell-free DNA estimate the risk of aneuploidy?
- How are structural fetal abnormalities detected and characterized?
- What is the role of carrier screening in identifying inherited risk?
Key concepts
- Screening versus diagnostic testing
- Gestational age and dating
- Detection rate and false-positive rate
- Aneuploidy risk estimation
- Cell-free DNA screening
- Structural anomaly detection
- Carrier and inherited-condition screening
Mechanisms
Antenatal evaluation layers complementary methods. Ultrasound establishes viability, number, and gestational age, and later surveys fetal anatomy and growth (Salomon, 2022; Whitworth, 2015). Maternal biochemistry and ultrasound markers are combined into risk algorithms for aneuploidy, while cell-free DNA in maternal plasma allows highly sensitive screening for the common trisomies (Gil, 2017; ACOG, 2020). Screening assigns a probability rather than a diagnosis; when risk is elevated, diagnostic testing such as chorionic villus sampling or amniocentesis is offered. Carrier screening operates separately, identifying parents who carry recessive or X-linked variants that could affect the fetus.
Clinical relevance
These methods structure how pregnancies are evaluated and how risk information is generated for counselling. Understanding the distinction between screening and diagnosis, and the meaning of detection and false-positive rates, is central to interpreting antenatal results. This entry describes how prenatal evidence is produced and is not a basis for individual diagnostic or management decisions.
Epidemiology
Screening and assessment are offered across pregnancies in most healthcare systems, and the performance of each method is described by its detection and false-positive rates in defined populations. Cell-free DNA screening achieves high detection rates for common trisomies, while combined first-trimester screening and ultrasound anatomy surveys remain widely used components of antenatal care (Gil, 2017; ACOG, 2020).
History
Antenatal assessment expanded through the late twentieth century from maternal serum alpha-fetoprotein testing for neural tube defects, through combined biochemical and ultrasound screening for Down syndrome, to the introduction of cell-free DNA analysis after 2011. Each step shifted the balance between detection, false positives, and invasive testing.
Key figures
- Kypros Nicolaides
- Nicholas Wald
- Diana Bianchi
- Laurent Salomon
Related topics
Seminal works
- gil-2017
- salomon-2022-isuog
- acog-2020-pb226
Frequently asked questions
- What is the difference between prenatal screening and prenatal diagnosis?
- Screening estimates the probability that a fetus is affected by a condition and applies to broad populations, whereas diagnosis (for example chorionic villus sampling or amniocentesis) confirms or excludes a specific condition in an individual pregnancy.
- Why is accurate pregnancy dating important for screening?
- Many screening tests are interpreted against gestational age, so accurate dating—usually by early ultrasound—is needed for the risk estimates and reference ranges to be valid.